Results 31 to 40 of about 22,537 (257)

Tau and tauopathies

open access: yesBrain Research Bulletin, 2016
Most neurodegenerative diseases are characterized by intracellular aggregates of insoluble proteins. As for the majority of these disorders, aetiology and pathogenesis are only poorly understood; current nosological concepts are largely based on these molecular signatures of protein aggregates which also provide valuable tools for neuropathological ...
Thomas, Arendt   +2 more
openaire   +2 more sources

Early alterations of neurovascular unit in the retina in mouse models of tauopathy

open access: yesActa Neuropathologica Communications, 2021
The retina, as the only visually accessible tissue in the central nervous system, has attracted significant attention for evaluating it as a biomarker for neurodegenerative diseases.
Fan Xia   +9 more
doaj   +1 more source

Tau and Tauopathies [PDF]

open access: yes, 2012
Tauopathies are age-related neurodegenerative diseases that are characterized by the presence of aggregates of abnormally phosphorylated tau. As tau was originally discovered as a microtubule-associated protein, it has been hypothesized that neurodegeneration results from a loss of the ability of tau to associate with microtubules.
Gloria, Lee, Chad J, Leugers
openaire   +2 more sources

Pneumonia initiates a tauopathy [PDF]

open access: yesThe FASEB Journal, 2021
Abstract Pneumonia causes short‐ and long‐term cognitive dysfunction in a high proportion of patients, although the mechanism(s) responsible for this effect are unknown. Here, we tested the hypothesis that pneumonia‐elicited cytotoxic amyloid and tau variants: (1) are present in the circulation during infection; (2) lead to impairment
Ron Balczon   +15 more
openaire   +2 more sources

Multi-organ comparison and quantification parameters of [18F]THK-5317 uptake in preclinical mouse models of tau pathology

open access: yesFrontiers in Physics, 2023
Introduction: Current small-animal PET instrumentation provides sufficient resolution, sensitivity, and quantitative accurate information on the radiotracer distribution within the whole body.
Thomas Wanek   +12 more
doaj   +1 more source

Astrogliopathy in Tauopathies [PDF]

open access: yesNeuroglia, 2018
Astrocytes are involved in many diseases of the central nervous system, not only as reactive cells to neuronal damage but also as primary actors in the pathological process. Astrogliopathy is a term used to designate the involvement of astrocytes as key elements in the pathogenesis and pathology of diseases and injuries of the central nervous system ...
openaire   +2 more sources

Spreading of P301S Aggregated Tau Investigated in Organotypic Mouse Brain Slice Cultures

open access: yesBiomolecules, 2022
Tau pathology extends throughout the brain in a prion-like fashion through connected brain regions. However, the details of the underlying mechanisms are incompletely understood.
Dhwani S. Korde, Christian Humpel
doaj   +1 more source

Clinical Spectrum of Tauopathies

open access: yesFrontiers in Neurology, 2022
Tauopathies are both clinical and pathological heterogeneous disorders characterized by neuronal and/or glial accumulation of misfolded tau protein. It is now well understood that every pathologic tauopathy may present with various clinical phenotypes based on the primary site of involvement and the spread and distribution of the pathology in the ...
Nahid Olfati   +3 more
openaire   +5 more sources

Tauopathy differentially affects cell adhesion molecules in mouse brain: early down-regulation of nectin-3 in stratum lacunosum moleculare.

open access: yesPLoS ONE, 2013
Cell adhesion molecules are important structural substrates, required for synaptic plasticity and synaptogenesis. CAMs differ widely in their expression throughout different brain regions and their specific structural and functional roles in the brain ...
Hervé Maurin   +8 more
doaj   +1 more source

Curcumin as a Holistic Treatment for Tau Pathology

open access: yesFrontiers in Pharmacology, 2022
Global forecasts for prevalence of Alzheimer’s Disease (AD) estimate that 152.8 million people will have dementia in 2050, a sharp rise from 57.4 million in 2019 (GBD 2019).
Lovesha Sivanantharajah, Amritpal Mudher
doaj   +1 more source

Home - About - Disclaimer - Privacy